Ivadantin is one of 148 small molecule programs targeting Osteomyelitis. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
46 competitors in Pregnancy
Femara
Bayer Aspirin
Marinol
Rayos
Ivadantin
Pifeltro
BEYFORTUS
Dihydroartemisinin-Piperaquine
Monoferric
Cimzia
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
IVADANTIN
NDA NDA012402
Jan 1, 1982
FURADANTIN
NDA NDA009175
Jan 1, 1982
FURADANTIN
NDA NDA008693
Sources
Details